 |
|
|
| |
VIR-2218 and VIR-3434 Therapy Is Efficacious in Preclinical Models of Hepatitis Delta Virus Infection
|
| |
| |
EASL 2023 June 21-24 Vienna
Jiayi Zhou,1 Hannah Kaiser,1 Tassilo Volz,2,3 Michael A. Schmid,4 Marc Luetgehetmann,2,3 Maura Dandri,2,3 Davide Corti,4 Lisa A. Purcell,1 Andreas S. Puschnik,1,* Florian A. Lempp1,*
1Vir Biotechnology, San Francisco, CA, USA; 2Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems Site, Germany; 4Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
*Co-corresponding authors
|
| |
|
|
|
|
|
